This NIH research grant aims to establish a deeper mechanistic understanding of TDP-43 pathology and its causal links to various phenotypic outcomes in neurodegenerative diseases. The funding supports investigations into mechanistic interactions between TDP-43 and other co-pathologies, such as TMEM106B. A key objective is to conduct comprehensive comparisons across different TDP-43 proteinopathies, including LATE (Limbic-predominant Age-related TDP-43 Encephalopathy), with or without Alzheimer’s disease neuropathologic change (AD-NC), as well as Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). These comparisons will encompass mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, and neuropathological aspects, ultimately advancing insights into these complex conditions.
Opportunity ID: 352214
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-148 |
| Funding Opportunity Title: | Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 – Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 06, 2024 |
| Last Updated Date: | Feb 06, 2024 |
| Original Closing Date for Applications: | Oct 04, 2024 |
| Current Closing Date for Applications: | Oct 04, 2024 |
| Archive Date: | Nov 09, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts County governments Special district governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Private institutions of higher education For profit organizations other than small businesses Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This FOA would support establishing deeper mechanistic insight and causal relationships between TDP-43 pathology and phenotypic outcomes, as well as mechanistic interactions between TDP-43 and other co-pathologies, such TMEM106B. Additionally, it would include comparisons (including mechanistic, molecular, structural, cellular, genetic, -omic, anatomical, neuropathological, etc.) between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-148.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 352214 Full Announcement-PAR-24-148 -> PAR-24-148-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00284735 | May 04, 2024 | Oct 04, 2024 | View |
Package 1
Mandatory forms
352214 RR_SF424_5_0-5.0.pdf
352214 PHS398_CoverPageSupplement_5_0-5.0.pdf
352214 RR_OtherProjectInfo_1_4-1.4.pdf
352214 PerformanceSite_4_0-4.0.pdf
352214 RR_KeyPersonExpanded_4_0-4.0.pdf
352214 PHS398_ResearchPlan_5_0-5.0.pdf
352214 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
352214 RR_Budget_3_0-3.0.pdf
352214 RR_SubawardBudget30_3_0-3.0.pdf
352214 PHS398_ModularBudget_1_2-1.2.pdf
352214 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
